home / stock / adms / adms news


ADMS News and Press, Adamas Pharmaceuticals Inc. From 05/12/21

Stock Information

Company Name: Adamas Pharmaceuticals Inc.
Stock Symbol: ADMS
Market: NASDAQ
Website: adamaspharma.com

Menu

ADMS ADMS Quote ADMS Short ADMS News ADMS Articles ADMS Message Board
Get ADMS Alerts

News, Short Squeeze, Breakout and More Instantly...

ADMS - The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Palm Beach, FL – May 12, 2021 – Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges during early childhood. Children show ASD-r...

ADMS - Adamas Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Adamas Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Adamas Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

ADMS - Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q1 2021 Results - Earnings Call Transcript

Adamas Pharmaceuticals, Inc. (ADMS) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss – Chief Financial O...

ADMS - Adamas Pharma EPS beats by $0.10, misses on revenue

Adamas Pharma (ADMS): Q1 GAAP EPS of -$0.36 beats by $0.10.Revenue of $19.31M (+33.4% Y/Y) misses by $0.35M.Press Release For further details see: Adamas Pharma EPS beats by $0.10, misses on revenue

ADMS - Adamas Reports First Quarter 2021 Financial Results

First quarter 2021 total revenues of $19.3 million, a 33% increase over first quarter 2020 GOCOVRI New paid prescriptions of 590, an 18% increase over first quarter 2020 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering med...

ADMS - Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027

Palm Beach, FL – May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  Symptoms generally develop sl...

ADMS - Adamas to Present at Upcoming BofA Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at ...

ADMS - Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss ...

ADMS - Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026

Palm Beach, FL – April 20, 2021 – While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic.  According to variou...

ADMS - Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson's disease presented at American Academy of Neurology (AAN) Annual Meeting

Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org ) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced ...

Previous 10 Next 10